This article is more than 5 years old. Information may no longer be current.

Ophthotech initiates phase 1 trial of anti-C5 aptamer for treating AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PRINCETON, N.J. — Ophthotech has enrolled the first patient in a phase 1 clinical trial of ARC1905, an anti-C5 complement factor aptamer being developed to treat age-related macular degeneration, the company announced in a press release.

The study will evaluate the safety and tolerability of ARC1905 in combination with an anti-VEGF agent, the release said.

"Preclinical and human genetic linkage studies strongly support the significant role of complement-mediated inflammation in both dry and wet AMD," Samir Patel, MD, president and chief executive officer of Ophthotech, said in the release. "We believe that anti-C5 aptamer blockade represents a potential breakthrough therapy for both wet and dry forms of AMD."

ARC1905 is the second of three compounds — the others are E10030 and volociximab (M200) — that Ophthotech is developing to treat AMD.